In particular, STA-21 and S3I-201 selectively target the DNA-binding domain of STAT3 and effectively suppress its activity in rhabdomyosarcoma, osteosarcoma, and breast cancer [22], [41]. This evidence concerns the gene STAT3 and osteosarcoma.